


# Cardiac and Non-cardiac Determinants of Exercise Capacity in Asymptomatic Non-Diabetic Chronic Kidney Disease Patients

Chinnappa S<sup>1,2</sup>, Mooney A<sup>2</sup>, El Nahas AM<sup>3</sup>, Tan LB<sup>2</sup>

<sup>1</sup>Sheffield Teaching Hospitals NHS Trust, <sup>2</sup>Leeds Teaching Hospitals NHS Trust, <sup>3</sup>University of Sheffield, United Kingdom



## INTRODUCTION

As there is growing interest in utilising the measures of exercise capacity such as peak O<sub>2</sub> consumption (VO<sub>2max</sub>) as markers of cardiac dysfunction in CKD, it is necessary to understand the differential role of cardiac output (CO) and peripheral O<sub>2</sub> extraction in determining exercise capacity in CKD. After all VO<sub>2max</sub> is a product of CO and C(a-v)O<sub>2</sub>.

Hypothesis: In the present study we tested the hypothesis that reduced peripheral O<sub>2</sub> extraction contributes significantly to impaired exercise capacity in CKD.

## METHODS

- A cross sectional study of 60 asymptomatic male non-diabetic CKD patients [CKD stages 2-5 (pre dialysis)] without primary cardiac disease.
- Historical data from age matched healthy male volunteers (n=101) was used as controls.
- Data from heart failure (HF) patients of NYHA class II&III (n=39) was used as positive controls.
- Specialised CPX test with CO<sub>2</sub> rebreathing technique was utilised to measure peak cardiac output non-invasively.
- CKD related biochemical parameters were also measured. Results are presented as mean±SD. P<0.05 is considered as significant.

## RESULTS

- The VO<sub>2max</sub> of the study groups were: Controls: 2.98±0.9, CKD2-3: 2.74±0.5, CKD4: 2.54±0.5, CKD5: 2.18±0.4 & HF: 1.57±0.4 l/min.
- Fig 1 shows the correlations of Peak CO and C(a-v)O<sub>2</sub> with VO<sub>2max</sub> and Fig 2 shows the relative differences in these parameters amongst the study groups (Healthy controls, CKD patients and Heart failure patients).
- Table 1 shows the significant correlates of VO<sub>2max</sub> on univariate analysis (all P<0.05). No correlation was demonstrated with Ca, PO<sub>4</sub>, PTH, total cholesterol or urine protein creatinine ratio.
- Multivariate analysis showed that PkCO (β=0.387), Hb (β=0.314), peak heart rate (β=0.236), BMI (β=0.22) and age (β=-0.194) were independent predictors of VO<sub>2max</sub> in CKD together accounting for >75% of its variability.




Fig 1: Correlation of peak O<sub>2</sub> consumption with Peak cardiac output and arterio-venous O<sub>2</sub> difference in CKD patients.

Table 1

| Parameters    | Correlation Coefficient (r) |
|---------------|-----------------------------|
| Pk heart rate | 0.48                        |
| Age           | 0.50                        |
| BMI           | 0.30                        |
| eGFR          | 0.51                        |
| Hb            | 0.60                        |




Fig 2: Peak cardiac output and arterio-venous O<sub>2</sub> difference across the study categories. The reduction in VO<sub>2max</sub> in CKD patients is influenced by greater reduction in C(a-v)O<sub>2</sub> than Pk CO in contrast to that of HF patients. # p<0.05 vs Controls for Pk CO. \*p<0.05 vs Controls for C(a-v)O<sub>2</sub>.

## CONCLUSION

- This study demonstrates the relative contributions of cardiac and non-cardiac determinants of exercise capacity in CKD.
- It highlights the significant role of peripheral O<sub>2</sub> extraction and hence the limitation in utilising VO<sub>2max</sub> as a surrogate of cardiac dysfunction.

We thank Yorkshire Kidney Research Fund and Sheffield Kidney Research Foundation for supporting the project